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The short QT syndrome (SQTS) is a rare condition involving accelerated ventricular 
repolarization, abbreviated rate-corrected (QTc) QT intervals on the electrocardiogram 
(ECG), poor rate adaptation of the QT interval, and an increased risk of atrial and ventricular 
arrhythmias and of sudden cardiac death.[1-3] In patients with genetic forms of SQTS, thus 
far gain-of-function mutations have been found in three potassium ion channel 
genes: KCNH2(responsible for “hERG” potassium channels that mediate the rapid delayed 
rectifier current, IKr); KCNQ1 (responsible for the α subunit of channels mediating the slow 
delayed rectifier current, IKs); KCNJ2 (which encodes Kir2.1 channels that carry inwardly 
rectifying K+ current).[1-3] Mutations to these genes are respectively responsible for SQT1, 
SQT2 and SQT3 variants of the syndrome. Loss-of-function mutations in both pore-forming 
(CACNA1C, SQT4) and accessory (CACNB2b, SQT5; CACND2D1, SQT6) subunits of L-type Ca 
channels have also been identified.[1-3] Treatment of the condition frequently involves the 
use of implantable cardioverter devices (ICDs), which protect against potentially fatal 
ventricular arrhythmias. Adjunct pharmacotherapy can be useful in delaying repolarization 
and decreasing arrhythmia risk. However, Class III drugs such as sotalol are ineffective in 
SQTS patients with KCNH2mutations that reduce affinity of the drug for the hERG channel. 
Current SQTS antiarrhythmic pharmacotherapy predominantly involves use of the Class Ia 
antiarrhythmic agent (hydro)quinidine.[1-3] 
 
There is at present no mammalian model that accurately reproduces a clinically identified 
SQTS genotype. Investigations of the mechanisms underlying arrhythmogenesis in the 
syndrome have therefore relied either on computer modelling[4] or the use of isolated 
hearts or tissue preparations to which pharmacological activators of potassium channels are 
applied; these induce an increase in repolarizing K+ current, if not through the precise 
mechanisms of identified SQTS mutations.[5, 6] The KATP channel opener pinacidil has been 
used with perfused left ventricular wedge and whole heart preparations to help identify 
arrhythmia substrate(s) in the condition.[5] In the canine wedge preparation, pinacidil has 
been shown to abbreviate ventricular repolarization and exacerbate transmural dispersion 
of repolarization.[5] In perfused rabbit hearts pinacidil abbreviates repolarization, increases 
dispersion of repolarization and shortens the effective refractory period (ERP).[7] These 
changes are broadly similar to those predicted from computer modelling of SQTS 
mutations.[4] Increased transmural dispersion of repolarization and abbreviated ERP 
increase vulnerability to re-entrant arrhythmia. Consistent with patient data, quinidine has 
been shown to be effective in the pinacidil-treated, intact perfused hearts at countering 
increased arrhythmia susceptibility, delaying repolarization and ERP, and prolonging post-
repolarization refractoriness (PRR).[1-3, 7] Pinacidil-treated, intact, paced rabbit hearts have 
also been used to pursue additional potential pharmacological treatments, with recent work 
showing prolongation of QT interval and of ERP and suppression of VF by both ranolazine 
and vernakalant.[8] In a new report in this volume of the journal, Frommeyer and colleagues 
have now employed the pinacidil-treated whole rabbit heart SQTS model, to demonstrate a 
potentially beneficial role for ivabradine in the SQTS.[9] 
 
Ivabradine was developed as a specific bradycardic agent, with clinical applications in 
coronary artery disease and heart failure.[10] It acts to slow the spontaneous action 
potential firing rate of the sinoatrial node (SAN), via inhibition hyperpolarisation-activated 
cyclic nucleotide-gated (HCN) channels that underpin the “funny” current, If, which 
participates in generating diastolic depolarisation.[10] The specificity of the drug for HCN 
channels enables a bradycardic effect without the concomitant negative inotropy that can 
occur with β blockers.[10] Recently, however, two independent reports have demonstrated 
that ivabradine inhibits hERG potassium channels over a concentration range which 
overlaps that for inhibition of If and HCN4, the dominant HCN isoform in the SAN.[11, 12] 
Moreover, in perfused, paced guinea-pig hearts ivabradine has been seen to prolong 
monophasic action potential duration and ERP at submicromolar concentrations that are 
relevant to the clinical concentration range.[11] Whilst such actions might be undesirable 
against a background of normal repolarization, a logical question that arises is whether they 
might be beneficial in a pathological setting of abbreviated ventricular repolarization? 
In their paper, Frommeyer and colleagues answer this question using ECG and monophasic 
ventricular AP recordings from perfused rabbit hearts.[9] The hearts were electrically paced 
following destruction of the AV node. In the absence of pinacidil, application of ivabradine 
concentrations between 1 and 5 μmol/L did not significantly prolong QT interval or 
monophasic AP duration (APD, measured at 90% repolarization), though at 5 μmol/L an 
increase of ERP was observed. The reason for the lack of overtly prolonged repolarization is 
unclear; though, as the authors comment, this may reflect the sample size used. However, 
repolarization-delay became marked when ivabradine (5 μmol/L) was applied after pinacidil 
(1 μmol/L). As expected, APD90, QT interval and ERP were abbreviated by pinacidil; they 
were subsequently lengthened, across a range of cycle lengths, by ivabradine. The extension 
of ERP exceeded that of APD90, resulting in an increase in PRR. Importantly, whilst pinacidil 
led to increased vulnerability to induction of ventricular fibrillation by programmed 
ventricular stimulation, ivabradine markedly suppressed this inducibility. To summarise: 
under the conditions of this study, ivabradine showed clear antiarrhythmic effects in the 
pinacidil SQTS model. 
 
The findings in this paper are important in two respects: first, they provide further evidence 
that ivabradine can exert clear electrophysiological actions that are independent of If/HCN 
channel inhibition; second, they provide proof-of-concept that, at least under the conditions 
of this study, ivabradine is antiarrhythmic against abbreviated ventricular repolarization. So, 
could the drug be beneficial in clinical SQTS? Possibly, yes, though further preclinical work is 
likely needed first. In particular, it would be useful to verify that submicromolar ivabradine 
concentrations closer to the clinical range produce similar effects to those seen here. 
Second, as the authors themselves note, one of the main SQT1 hERG mutations (N588K-
hERG) significantly reduces the ability of ivabradine to block the channel[11] and so the drug 
is unlikely to be effective in forms of SQT1 in which hERG channel inactivation is markedly 
impaired. Third, the paced preparation used in this study eliminates the bradycardic effect 
of ivabradine on the sinoatrial node and this would not be the case in the clinical setting. 
The significance of this point is that some forms of SQTS are themselves associated with 
bradycardia. For instance, one study has reported that up to 75% of SQT2 cases and 9% of 
non-SQT2 cases also show sick sinus syndrome/bradycardia.[3] Ivabradine would be 
expected to exacerbate these and so should be avoided in such cases. Also, as has been 
commented by others,[1] heterogeneity of repolarization and abnormality of the QT-RR 
relationship are likely to be greatest at slow rates, and this may facilitate susceptibility to 
tachyarrhythmia. Thus, if ivabradine were to be pursued further as a potential treatment for 
the SQTS, it may be important to establish whether or not the drug's prolongation of PRR 
would suffice to offset any increased vulnerability associated with drug-induced 
bradycardia. 
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